Australia’s Regeneus commences development of manufacturing process for their OA cellular therapy

Regeneus, an Australian regenerative medicine biotech, has commenced preparation (e.g. donor selection, manufacturing process development) for a Japan-based phase II clinical trial of Progenza, their cellular therapy under development for osteoarthritis (OA).

Read the full article by Japan Chemical Daily here.